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LAST MONTH'S ANNIVERSARYOF CHRJST'S BIRTHDAY and the onset of 1991 are fresh in mind, and provide a perspective for thinking about where we are in the growth of pharmacotherapy. Christians know Jesus Christ as God, and as a great teacher. He taught that man must turn from his old ways and enter into a new realm (the kingdom of God). Jesus said: "Marvel not that I said unto thee, ye must be born again" (John 3:7). He instructed that to go beyond the physical death into eternal life we must be born of the spirit. Or as Jesus put it: "that which is born of the flesh is flesh; and that which is born of the Spirit is spirit" (John 3:6). Our need to be born spiritually may, in part, explain why we like new beginnings. We look forward to a new home, new car, new job, or a new day. The commencement of a new year is a time to start afresh. It is an opportunity to shed the past and be reborn. It is a time to reflect on where we have been and consider where we are going.
With this issue, we initiate the celebration of the 25th Anniversary year of publication of DICP, The Annals of Pharmacotherapy. We also celebrate a quarter century of a movement that began with a clinical and patient-care emphasis in pharmacy, and has led to the creation of the specialty of pharmacotherapy. In reviewing the past 25 years, I believe pharmacy historians may well regard these years as the most significant in the history of American pharmacy from the standpoint of how the pharmacy practitioner has started to move from a merchant to a healthcare provider. However, we have not been decisive in cutting off our mercantile desires, and to experience a true rebirth we must not attempt to cling to the past.
In the previous 100 years, pharmacy has seen the pharmaceutical industry evolve rapidly into the giant that it is today. The impact this had on the pharmacist caused the metamorphosis of the practitioner, stripping away the traditional function of compounding, and leaving in place the merchant. Now we are slowly approaching the stage of development wherein the merchant is being replaced by the pharmacotherapist. Unfortunately there are still many pharmacy practitioners who are trying to be both a merchant and a clinician, and others who are unable to part with the past. The blame for this condition does not rest entirely on practitioners for they are shaped by an educational system that has not completely matured. Johnson and Stimmel have noted that "clinical pharmacy education has ignored community practice, with few if any clinical faculty devoted to the area."! Although pharmacy schools still have deficiencies, the evolution of pharmacy education during the past 25 years has been exciting to watch. As a former faculty member at two pharmacy schools, and as a member of their curriculum committees, I have enjoyed seeing the fruit of much labor brought to harvest. Virtually all schools have radically changed their objectives, curricula, course content, methods of instruction; and some have moved their physical locations. It is interesting to look back to the first year of the journal, 1967, and read comments on the future of pharmacy education from people like Lloyd M. Parks, Ph.D., the dean of the pharmacy school at Ohio State University, at a time when the seeds of pharmacotherapy were first being planted. Parks said:
In his potential role as a consultant on drugs there is a great need for the pharmacist to become more patient-oriented and diseaseoriented rather than being so heavily product-oriented. This would permit him to communicate more effectively with the physician as well as with his patrons. One of the pharmacist's difficulties now in communicating with the physician is that the pharmacist does not understand the language of the latter.'
Since then much progress has been made; however, there is one problem that needs to be resolved. Should all pharmacists receive a professional doctorate degree? Professional doctorates in pharmacy were awarded as long ago as 1905 but did not become accepted as a six-year degree until initiated by the University of Southern California in 1950. This followed directly after the results of the Pharmaceutical Survey, which were released in 1949 and called for a six-year curriculum leading to a professional doctorate. Needless to say, it was about 20 years ahead of its time. The debate over this issue has surfaced many times in the pages of this journal; most recent articles were by the American College of Clinical Pharmacy, Nahata, Vlasses, and Lemberger.>? Furthering the discussion is a special article by Gerhard Levy, Phann.D. in this issue (see page 94). Because this topic has remained a controversy for more than 40 years, and because Levy has the distinction of being the first Phann.D. recipient to earn a place of prominence in pharmacy as well as the first Phann.D. appointed to a faculty, we are focusing on this article in commemorating our 25th Anniversary. Perhaps Levy's article will serve to bring the issue to a head, and end the debate before the year 2000. Again, I maintain that we must sever our past and be reborn. My thoughts about how this should be done will probably not be any more popular than they were when the idea was first proposed in 1963 by Glenn L. Jenkins, Ph.D., the dean of the School of Pharmacy and Pharmacal Sciences, Purdue University. This idea was described by Francke as follows:
This is an age of specialization. Pharmacy would be strengthened immeasurably if it adopted a strong four-year course leading to a Bachelor of Science degree and then required everyone to take an additional degree to prepare him to practice his specialty. Thus, following their B.S. degree, pharmacists entering hospital or community practice would obtain either a Master of Pharmacy or a Doctor of Pharmacy for specialization in professional practice. Those wishing to enter education or research, to specialize in the physical or biological sciences, to go into pharmaceutical industry, or to specialize in management would take either a Master of Science or a Doctor of Philosophy degree following their Bachelor of Science degree .... This program would enable pharmacy to break the vicious cycle of having its educational pattern geared almost exclusively toward preparing pharmacists for community practice. The assumption that education for community practice is the proper basis for all the specialties of pharmacy is absurd. What is needed is a flexible educational program in pharmacy that will permit students to take advantage of the great diversity of practice that is widely available within the profession. The Jenkins program would provide this flexibility by establishing the four-year Bachelor of Science degree as the base-line from which students could elect either an advanced professional degree or an advanced research degree. Some students may not choose or may not be qualified for either of these degrees.
Thus, the Bachelor of Science degree might well be the terminal degree for a number of students. These people would find employment in such areas as medical sales, medical writing, as chemists or analysts or technicians in the industry, or in other positions. In other words, a Bachelor of Science degree would no longer permit one to practice pharmacy but, rather, would serve only as the prerequisite for an advanced professional or scientific degree. At the same time, it would form the base for graduate work for qualified students and, thus, would tend to draw superior students into colleges of pharmacy,"
We are treading the same water in the Pharm.D. issue; we keep going over it hoping to come to a resolution. Maybe it will take strong leadership from some unknown quarter to resolve it; perhaps it will require decisive action such as proposed by the American Council on Pharmaceutical Education." Or possibly it will require pharmacy to put its past permanently away, and to be reborn with some idea not yet conceived. Our intention is to continue to use the pages of DICP to probe the future and to seek new ideas. As we embark on our second quarter-century, we believe that the journal is entering into an exciting new realm as pharmacotherapy takes on the mantle of leadership for the profession.
The last 25 years have brought about the beginning of pharmacotherapy specialists who are indispensable members of the healthcare team. Their certification will begin this year in August. This process, having begun with nuclear pharmacists, has never before occurred in the history of the profession. As we enter into our next quarter century, we will continue to support the pharmacotherapy movement. Now at age 25, DICP has been reborn; we expect it to continue as a leader in the profession as its contributors move the journal and the specialty of pharmacotherapy into vast unexplored areas that science is unfolding.
